Type 2 diabetes mellitus in adolescence: Lipid and cardiovascular risk factors

Current Diabetes Reports

Volumn 3, Issue 3, 2003, Pages 255-262

  Jones, Kenneth Lee ^a   Dewan, Asheesh Kumar ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BILE ACID; CHOLESTEROL; CLOFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CREATINE KINASE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LESCOL XL; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; MACROLIDE; MEVINOLIN; PRAVASTATIN; RESIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; HYPOCHOLESTEROLEMIC AGENT;

ADOLESCENT; ADRENERGIC SYSTEM; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; COMORBIDITY; CONSTIPATION; DIET THERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSLIPIDEMIA; FLATULENCE; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; JUVENILE DIABETES MELLITUS; KINESIOTHERAPY; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; CHILD; DIABETIC ANGIOPATHY; DRUG COMBINATION; HYPERLIPIDEMIA; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; RISK FACTOR;

ADOLESCENT; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHILD; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; METABOLIC SYNDROME X; RISK FACTORS;

EID: 0042521165     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-003-0073-2     Document Type: Review

References (73)

1. Kwiterovich PO: Diagnosis and management of familial dyslipoproteinemia in children and adolescents. Pediatr Clin North Am 1990,37:1489-1523.
2. Stewart KJ: Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health. JAMA 2002, 288:1622-1631.
3. Dean H, Flett B: Natural history of type 2 diabetes diagnosed in childhood: long term follow-up in young adult years. Diabetes 2002, 51:A24.
4. Wingard DL, Barrett-Connor E: Heart disease and diabetes. In Diabetes in America, 2nd edn. Edited by Harris MI. Washington, DC: U.S. Government Printing Office; 1995:429-448.
5. Pyörälä K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987, 3:463-524.
6. Haffner SM, Lehto S, Ronnemaa T: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
7. Perrone J, Hollander JE, De Roos F: Cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med 1998,339:1083-1084.
8. Malmberg K Yusuf S, Gerstein HC, et al.: Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction : results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000, 102:1014-1019.
9. Herlitz J, Karlson BW, Lindqvist J, et al.: Rate and mode of death during five years of follow-up among patients with acute chest pain with and without a history of diabetes mellitus. Diabet Med 1998, 15:308-314.
10. Newman AB, Siscovick DS, Manolio TA, et al.: Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Circulation 1993, 88P:837-845.
11. Jude EB, Oyibo So, Chalmers N, Boulton AJ: Peripheral arterial disease in diabetic and nondiabetic patients. Diabetes Care 2001, 24:1433-1437.
12. Uusitupa MI, Niskanen LK, Siitonen O, et al.: 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin dependent diabetic and nondiabetetic subjects. Circulation 1990, 82:27-36.
13. Diabetes-related amputations of lower extremities in the Medicare population - Minnesota, 1993-1995 [no authors listed]. MMWR Morb Mortal Wkly Rep 1998, 47:649-652.
14. Jamrozik K, Broadhurst RJ, Forbes S, et al.: Predictors of death and vascular events in the elderly. Stroke 2000, 31:863-868.
15. Folsom AR, Rasmussen ML, Chambless LE, et al.: Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. Diabetes Care 1999, 22:1077-1083.
16. Kuusisto J, Mykkanen L, Pyorala K, et al.: Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke 1994, 25:1157-1164.
17. Jorgensen H, Nakayama H, Raaschou HO, et al.: Stroke in patients with diabetes: the Copenhagen Stroke Study. Stroke 1994, 25:1977-1984.
18. Luchsinger JA, Tang MX, Stern Y, et al.: Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001, 154:635-641.
19. Hankey GJ, Jamrozik K, Broadhurst RJ, et al.: Long term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 1998, 29:2491-2500.
20. Tuomilehto J, Rastenyte D, Jousilahti P, et al.: Diabetes mellitus as a risk factor for death from stroke. Stroke 1996, 27:210-215.
21. Haffner SM, Stern MP, Hazuda HP, et al.: Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990, 263:2893-2898.
22. Apedo MT, Sowers JR, Banerji MA: Cardiovascular disease in adolescents with type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2002, 15(suppl 1):519-523.
23. Paulsen EP, Richenderfer L, Ginsberg-Fellner F: Plasma glucose, free fatty acids, and immunoreactive insulin in sixty-six obese children. Studies in reference to a family history of diabetes mellitus. Diabetes 1968, 17:261-269.
24. Dabelea D, Hanson RL, Bennett PH, et al.: Increasing diabetes in American Indian children. Diabetologia 1998, 41:904-910.
25. Pinhas-Hamiel O, Dolan LM, Daniels SR, et al.: Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr 1996, 128:608-615.
26. Scott CR, Smith JM, Cradock MM, et al.: Characteristics of youth-onset non-insulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. Pediatrics 1997, 100:84-91.
27. Glaser NS, Jones KL: Non-insulin-dependent diabetes mellitus in Mexican-American children; West J Med 1998, 168:11-16.
28. Rosenbloom AL, Joe JR, Young RS, et al.: Emerging epidemic of type 2 diabetes in youth. Diabetes Care 1999, 22:345-354.
29. Fagot-Campana A, Pettitt DJ, Engelgau MM, et al.: Type 2 diabetes among North American children and adolescents: an epidemiological review and a public health perspective. J Pediatr 2000, 136:664-672.
30. Fagot-Campagna A, Balkau B, Simon D, et al.: High free fatty acid concentration: an independent risk factor for hypertension in the Paris Prospective Study. Int J Epidemiol 1998, 27:808-813.
31. Taha D: Hyperlipidemia in children with type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2002, 15:505-507.
32. Type 2 diabetes in children and adolescents. American Diabetes Association [no authors listed]. Diabetes Care 2000, 23:381-389.
33. Dabela D, Pettitt DJ, Jones KL, et al.: Type 2 diabetes mellitus in minority children. An emerging problem. Endocrinol Metab North Am 1999, 28:709-729.
34. Osei K, Schuster DP, Owusu, et al.: Race and ethnicity determine serum insulin and C-peptide concentration and hepatic insulin interaction and insulin clearance: comparative studies of three populations of West African ancestry and white Americans. Metabolism 1997, 46:53-58.
35. Goran MI, Bergman RN, Cruz ML, et al.: Insulin resistance and associated compensatory responses in African-American and Hispanic children. Diabetes Care 2002, 25:2184-2190.
36. Jones KL: Why test the children? Understanding insulin resistance, its complications, and its progression. Diabetes Care 2002, 25:2350-2351.
37. Reaven P, Nader PR, Berry C, et al.: Cardiovascular disease insulin risk in Mexican-American and Anglo-American children and mothers. Pediatrics 1998, 101:E12.
38. Palinski W, Napoli C: The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis. FASEB J 2002, 16:1348-1360.
39. Napoli C, Glass CK, Witztum JL, et al.: Influence of maternal hypercholesterolemia during pregnancy on the progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet 1999, 354:1234-1241.
40. Zieske AW, Malcom GT, Strong JP: Natural history and risk factors of atherosclerosis in children and youth: the PDAY study. Pediatr Pathol Mol Med 2002, 213:213-237.
41. McGill HC, Herderick EE, McMahan CA, et al.: Atherosclerosis in youth. Minerva Pediatr 2002, 54:437-447.
42. McGill HC, McMahan AC, Malcom GT, et al.: Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Arterioscler Thromb Vasc Biol 1995, 15:431-440.
43. Berenson GS, Wattingney WA, Tracy RE, et al.: Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). Am J Cardiol 1992, 70:851-858.
44. Celermajer DS, Sorensen KE, Gooch VM, et al.: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340:1111-1115.
45. Pomilio M, Mohn A, Verrotti A, Chiarelli F: Endothelial dysfunction in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002, 15:343-361.
46. Management of dyslipidemia in adults with diabetes. American Diabetes Association [no authors listed]. Diabetes Care 2002, 25:S74-S77.
47. Hobbs HH, Brown MS, Goldstein JL: Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992, 1:445-466.
48. Risk of fatal coronary heart disease in familial hypercholesterolemia. Scientific Steering Committee on behalf of the Simon Broome Register Group [no authors listed]. BMJ 1991, 303:893-896.
49. Tonstad S: Role of lipid-lowering pharmacotherapy in children. Paediatr Drugs 2000, 2:11-22.
50. American Academy of Pediatrics. National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents [no authors listed]. Pediatrics 1992, 89(3 Pt 2):525-584.
51. Prevention of coronary heart disease: scientific background and new clinical guidelines. European Atherosclerosis Society International Task Force for Prevention of Coronary Heart Disease [no authors listed]. Nutr Metab Cardiovasc Dis 1992, 2:113-156.
52. Äkerblom HK, Chandra RK, Franklin FA, et al.: Conclusions, guidelines and recommendations from the IUNS/WHO workshop: nutrition in the pediatric age group and later cardiovascular disease. J Am Coll Nutr 1992, 11(suppl):1S-2S,
53. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol Levels in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of high Blood Cholesterol in Adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486-2497.
54. Nutrition recommendation and principles for people with diabetes mellitus [no authors listed]. Diabetes Care 1994, 17:519-522.
55. Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol: the Dietary Intervention study in Children (DISC). Writing Group for the DISC Collaborative Research Group [no authors listed]. JAMA 1995, 273:1429-1435.
56. Connor WE, Connor SI: Importance of diet in the treatment of familial hypercholesterolemia. Am J Cardiol 1993, 72:42D-53D.
57. Kaplan RM, Toshima MT: Does a reduced fat diet cause retardation in child growth? Prev Med 1992, 21:33-52.
58. Tonstad S, Ose L: Colestipol tablets in adolescents with familial hypercholesterolemia. Acta Paediatr 1996, 85:1080-1082.
59. Donovan JM, Stypinski D, Stiles MR, et al.: Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther 2000, 14:681-690.
60. Kesaniemi YA, Grundy SM: Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA 1984, 251:2241-2246.
61. Vinik AI, Colwell JA: Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Hyperlipidemia in Diabetes Investigators. Diabetes Care 1993, 16:37-44.
62. Steinmetz J, Morin C, Panek E, et al.: Biological variations in hyperlipidemic children and adolescents treated with fenofibrate. Clin Chim Acta 1981, 112:43-53.
63. Buyukcelik M, Anarat A, Bayazit AK, et al.: The effects of gemfibrozil in hyperlipidemia in children with persistent nephrotic syndrome. Turk J Pediatr 2002, 44:40-44.
64. Weitz-Schmidt G: Statins as anti-inflammatory agents. Trends Pharmacol Sci 2002, 23:482-486.
65. Sinzinger H, Schmid P Pirich CH, et al.: Treatment of hypercholesterolaemia in children. Lancet 1992, 340:548-549.
66. Knipscheer HC, Boeden CCA, Kastelein JJP, et al.: Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 1996, 39:867-871.
67. Lambert M, Lupien P-J, Gagne C, et al.: Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Pediatrics 1996, 97:619-628.
68. Stein EA, Illingworth DR, Kwiterovich PO Jr, et al.: Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 1999, 281:137-144.
69. De Jongh S, Ose L, Szamosi T, et al.: Efficacy and safety of statin therapy in children with familial hypercholesterolemia. Circulation 2002, 106:2231-2237.
70. Schectman G, Hiatt J: Dose response characteristics of cholesterol-lowering drug therapies: implications for treatment. Ann Intern Med 1996, 125:990-1000.
71. Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990, 264:71-75.
72. Hutcheson AC, Moral A, Jones AF: Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia. J Clin Pharm Ther 1994, 19:387-389.
73. McCrindle BW, Heiden E, Cullen-Dean G, et al.: A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr Res 2002, 51:715-721.